New treatment gave hope to patients with the hardest forms of TB in Kyrgyzstan. The U.S. Embassy in the Kyrgyz Republic reported.
USAID and the Kyrgyz Republic shared a tremendous achievement in the battle against Extensively Drug Resistant Tuberculosis (XDR-TB). Doctors pronounced the first two XDR-TB patients undergoing new individualized treatment regimens to be cured.
This exciting victory stands in contrast to the stark reality of the 90% treatment failure rate associated with XDR TB in the Kyrgyz Republic.
The Ministry of Health introduced a new treatment method with the use of the new drugs bedaquiline or delamanid 18 months ago.
The standard regimen previously used in the treatment of both multi drug-resistant TB (MDR-TB) and XDR TB took two years to complete, during which patients had to take 14,600 pills and receive 240 injections.
As reported, the recommended by the World Health Organization (WHO), the new treatment can cure even the hardest forms of TB. Some current patients have suffered for years both from poorly controlled and recurring infections, and from harmful side effects inflicted by past-generation medicines. Currently, more than 350 patients are benefiting from new individualized regimens throughout the country, with 60% of them on new drugs.